USPTO Examiner CONIGLIO AUDREA JUNE BUCKLEY - Art Unit 1617

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18910243SKINCARE COOLING PRODUCT, METHOD OF MAKING, AND METHOD OF USING THE SAMEOctober 2024April 2025Allow611YesNo
18739871HORTICULTURAL HYDROGELSJune 2024December 2024Allow620NoNo
18703622PERFUMING COMPLEX, PERFUMING COMPOSITION AND PERFUMED AQUEOUS COMPOSITION OF NATURAL ORIGINApril 2024March 2025Allow1010NoNo
18290914STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOFJanuary 2024March 2025Allow1311YesNo
18400346ORALLY AVAILABLE ARTICLES CONTAINING AT LEAST ONE STABILIZED SUPPLEMENT THEREINDecember 2023December 2024Allow1101NoNo
18541510PHARMACEUTICAL COMPOSITIONS FOR VAPORIZATION AND INHALATIONDecember 2023October 2024Abandon1001NoNo
18538617DETERGENT COMPOSITIONS FOR WASHING URUSHIOL AND METHODS OF TREATING URUSHIOL INDUCED CONTACT DERMATITISDecember 2023February 2025Allow1410NoNo
18498005MANUFACTURING METHOD OF CASINGOctober 2023March 2025Abandon1610YesNo
18488513AMORPHOUS SOLID DISPERSIONSOctober 2023September 2024Allow1110YesNo
18286774ANTIMICROBIAL COMPOSITIONOctober 2023March 2025Abandon1720NoNo
18468199AMORPHOUS SOLID DISPERSIONSSeptember 2023April 2025Allow1911NoNo
18234755SYSTEM FOR MIXING GERMICIDALLY ACTIVE SOLUTIONS, ON-SITE, FOR DAIRY/AGRICULTURAL HYGIENE PURPOSESAugust 2023February 2024Allow610NoNo
18225849PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOFJuly 2023August 2024Allow1300NoNo
18221784PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOFJuly 2023April 2024Allow900YesNo
18345797AQUEOUS COSMETICJune 2023March 2025Abandon2011NoNo
18323115NEW PHARMACEUTICAL DEVICE FOR USE IN INTRANASAL ADMINISTRATIONMay 2023March 2025Allow2131YesNo
181957121,2-ALKANEDIOLS AND A PROCESS FOR THEIR PRODUCTIONMay 2023March 2025Abandon2210NoNo
18188537COMPOSITION FOR TREATING ATOPY OR PRURITUS COMPRISING N-ACETYL OR N-ACYL AMINO ACIDMarch 2023March 2025Abandon2420YesNo
18026663MOISTURIZING ANTIBACTERIAL COMPOSITIONMarch 2023April 2025Abandon2540NoNo
18091736PHARMACEUTICAL FORMULATIONS OF QUINOLINESDecember 2022May 2024Allow1721YesNo
18013770PHARMACEUTICAL COMPOSITION COMPRISING ORGANOID AND ANTI-INFLAMMATORY AGENT FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASEDecember 2022May 2023Allow400NoNo
18081979COMPOSITION FOR INHIBITING ALPHA-GLUCOSIDASE AND APPLICATION THEREOFDecember 2022July 2023Allow710NoNo
17986552FABRICATION OF NANOWIRES AND HIERARCHICALLY POROUS MATERIALS THROUGH SUPERCRITICAL CO2 ASSISTED NEBULIZATIONNovember 2022November 2024Allow2410NoNo
17802885COMPOSITION FOR DISPERSING A LIPOSOLUBLE COMPOUND IN AN AQUEOUS PHASEAugust 2022March 2025Allow3100NoNo
17891835TOPICAL THERAPEUTIC FORMULATIONSAugust 2022March 2024Allow1921YesNo
17866115STABLE PHARMACEUTICAL COMPOSITIONS OF CLONIDINEJuly 2022October 2024Allow2831YesNo
17812068FORMULATIONS FOR WEIGHT LOSS AND METHODS OF USEJuly 2022September 2023Allow1411NoNo
17855206COMPOSITION FOR STIMULATING FACIAL HAIR GROWTH AND METHODS OF MANUFACTURING A COMPOSITION FOR STIMULATING FACIAL HAIR GROWTHJune 2022January 2024Allow1931YesNo
17834260FIXED DOSE PHARMACEUTICAL COMPOSITION OF VALSARTAN AND SACUBITRILJune 2022July 2023Allow1310NoNo
17748886PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOFMay 2022February 2023Allow911NoNo
17770574METHODS FOR WEED GROWTH CONTROLApril 2022May 2025Allow3711YesNo
17721699SYNTHESIS OF TAUROLIDINE, PURITY PROFILES AND POLYMORPHSApril 2022April 2023Allow1230YesNo
17659063AMORPHOUS SOLID DISPERSIONSApril 2022July 2023Allow1511NoNo
17766272COMPOSITIONS AND METHODS FOR MEALYBUG MONITORING AND CONTROLApril 2022May 2025Abandon3701NoNo
17764773NANOFIBRE MATRIX MADE OF NATURAL POLYMERS WITH NATURAL FUNCTIONAL INGREDIENTS FOR COSMETIC PRODUCTSMarch 2022March 2025Abandon3621NoNo
17706759SUCCINATE DEHYDROGENASE INHIBITORS FOR BREAKING DORMANCYMarch 2022September 2024Allow3011NoNo
17655143AMORPHOUS SOLID DISPERSIONSMarch 2022June 2023Allow1501NoNo
17696133ANTIMICROBIAL AGENTS AND COMPOSITIONS AND USES THEREOFMarch 2022November 2024Allow3200NoNo
17682658DEHYDRATED SOAP AND CLEANER TABLET COMPOSITIONFebruary 2022October 2023Abandon2040YesNo
17638701Compositions Comprising Cannabinoid Ions that are Dissolved in GlycerolFebruary 2022May 2025Allow3901NoNo
17634822BENAZOLIN-CHOLINE AND ITS USE IN THE AGROCHEMICAL FIELDFebruary 2022June 2025Allow4011NoNo
17668678COMPOSITION FOR TREATING ATOPY OR PRURITUS COMPRISING N-ACETYL OR N-ACYL AMINO ACIDFebruary 2022April 2025Allow3860YesNo
17586014MIXTURES AND FORMULATIONS COMPRISING AN ALKYL AMMONIUM EDTA SALTJanuary 2022November 2024Allow3421NoNo
17567065Tattoo TowelettesDecember 2021September 2023Abandon2030YesNo
17614838LIQUID COMPOSITION COMPRISING MEFENTRIFLUCONAZOLENovember 2021April 2025Abandon4110NoNo
17456510AQUEOUS COSMETICNovember 2021July 2023Abandon1910NoNo
17531407COMPOSITIONS FOR TREATING THE HAIRNovember 2021February 2024Allow2711NoNo
17611752COMPOSITIONS AND METHODS FOR SKIN REJUVENATIONNovember 2021December 2023Allow2510NoNo
17610284AGENT FOR PROTECTION AGAINST ATMOSPHERIC POLLUTANTS AND COMPOSITION FOR PROTECTION AGAINST ATMOSPHERIC POLLUTANTSNovember 2021August 2023Abandon2110NoNo
17509828DETERGENT COMPOSITIONS FOR WASHING URUSHIOL AND METHODS OF TREATING URUSHIOL INDUCED CONTACT DERMATITISOctober 2021August 2023Allow2110NoNo
17502172SENSORY ENHANCED AND MOISTURIZING HAND SANITIZER FORMULATIONS UTILIZING NON-EMULSION TECHNOLOGIESOctober 2021March 2024Abandon2920NoNo
17594337COMPOSITION FOR A TOPICAL APPLICATION ON THE SKINOctober 2021June 2025Abandon4431YesNo
17439284MICROPARTICLES BASED ON ESTER DERIVATIVES OF HYALURONAN, METHOD OF PRODUCTION, COMPOSITION COMPRISING THEREOF AND USE THEREOFSeptember 2021August 2023Abandon2301NoNo
17437734HERBICIDALLY ACTIVE 3-PHENYLISOXAZOLINE-5-CARBOXAMIDES OF S-CONTAINING CYCLOPENTENYLCARBOXYLIC ESTERSSeptember 2021August 2024Allow3610NoNo
17433719PHARMACEUTICAL COMPOSITIONS FOR USE IN TREATING PAINAugust 2021May 2025Allow4511NoNo
17383516KETOCONAZOLE OPHTHALMIC PREPARATIONS CONTAINING TRANS-ETHOSOMAL DRUG NANOPARTICLESJuly 2021February 2022Allow620YesNo
17424162SOLID SOAPJuly 2021June 2023Allow2310NoNo
17360235LOW VISCOSITY EMULSION COSMETIC COMPOSITIONJune 2021March 2024Allow3211NoNo
17416892SOLID COSMETIC COMPOSITION CONTAINING ANHYDROUS SPHEROIDS DISPERSED IN A SOLID CONTINUOUS AQUEOUS PHASEJune 2021August 2024Allow3821NoNo
17414774SUBSTITUTED PYRIDINYLOXYBENZENES AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL AGENTSJune 2021April 2024Allow3400NoNo
17338578ANTIFUNGAL COMPOUNDSJune 2021September 2024Abandon3910NoNo
17294835PREPARATION COMPRISING A DISPERSION OF PHOSPHOLIPIDS AND FATTY ACID SALTSMay 2021September 2024Allow4011NoNo
17319221METHODS, PARENTERAL PHARMACEUTICAL FORMULATIONS, AND DEVICES FOR THE PREVENTION OF OPIOID OVERDOSEMay 2021April 2023Abandon2330YesNo
17313957COMPOSITIONS AND METHODS FOR ENHANCED CO2 CAPTURE AND STORAGEMay 2021December 2023Allow3110NoNo
17238826Non-toxic, alcohol-free disinfectant and sanitizing compositionApril 2021October 2024Abandon4211NoNo
17286569TREATMENT OF PORTAL HYPERTENSION AND CIRRHOSISApril 2021October 2023Allow3011YesNo
17233732USE OF CHAETOMIUM GLOBOSUM STRAIN IN CONTROLLING FUSARIUM CROWN ROT OF WHEATApril 2021March 2024Allow3520NoNo
17286164Bioflavonoid Compositions and Their Use for Water Purification and Food PreservationApril 2021January 2024Allow3320NoNo
17284588HERBICIDE COMPOSITIONApril 2021December 2024Allow4411YesNo
17284287EXTERNAL PREPARATION FOR CONCEALING ROUGHNESSApril 2021September 2024Allow4130NoNo
17282408ANTIMICROBIAL COMPOSITIONS COMPRISING WOLLASTONITEApril 2021July 2024Abandon4010NoNo
17213599METHOD FOR SMOKING CESSATIONMarch 2021May 2025Allow5050NoNo
16640989Device in the form of a composition felt pen to instantly color the white hairs of the beard and hair.March 2021February 2024Abandon4811YesNo
17196379METHOD FOR ENHANCING SCALP ACTIVE DEPOSITIONMarch 2021August 2023Allow2910NoNo
17271587TITANIUM OXIDE POWDER, AND COSMETIC AND DISPERSION USING THE SAMEFebruary 2021February 2023Allow2300NoNo
17182233CASING AND MANUFACTURING METHOD THEREOFFebruary 2021August 2023Allow3011YesNo
17270515AQUEOUS COMPOSITIONS OF TOPRAMEZONEFebruary 2021May 2025Abandon5121NoNo
17270334HETEROCYCLE-CONTAINING AMINO ACID COMPOUND AND SALT THEREOF, COMPLEX, COMPOSITION, FERTILIZER AND PLANT GROWTH REGULATORFebruary 2021November 2023Allow3300NoNo
17176644Hand Sanitizing CompositionsFebruary 2021December 2023Abandon3420YesNo
17268304IMPROVEMENTS IN RELATION TO THE MANUFACTURE OF PERSONAL CLEANSING COMPOSITIONSFebruary 2021May 2022Allow1521YesNo
17167635IMMUNOSUPPRESSANT FORMULATIONFebruary 2021March 2024Abandon3821NoNo
17163871SUSTAINED DRUG RELEASE SHEET FOR TREATING NERVE INJURYFebruary 2021March 2024Allow3721YesNo
17162142METHODS FOR INHIBITING MICROBE GROWTHJanuary 2021March 2022Allow1410YesNo
17141693COSMETIC COMPOSITION COMPRISING ROSE STEM CELL-DERIVED EXOSOME AS EFFECTIVE INGREDIENTJanuary 2021April 2023Allow2710NoNo
17130340PHARMACEUTICAL COMPOSITION COMPRISING PLASMINOGEN AND USES THEREOFDecember 2020December 2022Allow2400NoNo
17114936LOW BENZALKONIUM CHLORIDE BIMATOPROST OPHTHALMIC COMPOSITIONS WITH EFFECTIVE PENETRATION & PRESERVATION PROPERTIESDecember 2020August 2022Abandon2040YesNo
17113246MUCOADHESIVE POLYMER COMPOSITIONSDecember 2020July 2024Abandon4321NoNo
17110920SKINCARE COSMETIC COMPOSITIONDecember 2020April 2023Abandon2821YesNo
17049524ACID ADDITION SALT OF PYRIMETHAMINEOctober 2020August 2023Abandon3401NoNo
17070476WIPE SUBSTRATE HAVING RESIDUAL DISINFECTANT PROPERTYOctober 2020August 2022Abandon2210NoNo
17041362TRIAZINE COMPOUND AND USE THEREOFSeptember 2020January 2024Allow4011YesNo
17023625PHARMACEUTICAL COMPOSITIONS COMPRISING SILICA MICROSPHERESSeptember 2020August 2023Allow3521YesNo
17011438TUMESCENT CONTRAVENOM DRUG DELIVERYSeptember 2020May 2023Abandon3330YesNo
16971785FUNGICIDAL COMPOSITIONS OF MEFENTRIFLUCONAZOLEAugust 2020October 2023Allow3810NoNo
16994458CO-CROSSLINKED HYALURONIC ACID-SILK FIBROIN HYDROGELS FOR IMPROVING TISSUE GRAFT VIABILITY AND FOR SOFT TISSUE AUGMENTATIONAugust 2020March 2024Abandon4320NoNo
16963537PATCHJuly 2020July 2021Allow1210NoNo
16928724METHODS AND COMPOSITIONS FOR MODULATING MYOFIBROBLAST ACTIVITIESJuly 2020July 2024Allow4841YesNo
16923937GELATINOUS COMPOSITION AND PRODUCTION METHOD THEREFORJuly 2020September 2022Abandon2621YesNo
16917269Degradable Removable Implant for the Sustained Release of An Active CompoundJune 2020March 2022Allow2111NoNo
16958389EXTERNAL COMPOSITION CONTAINING ASCORBIC ACID AND/OR SALT THEREOFJune 2020December 2024Allow5440NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CONIGLIO, AUDREA JUNE BUCKLEY.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
29
Examiner Affirmed
21
(72.4%)
Examiner Reversed
8
(27.6%)
Reversal Percentile
42.3%
Lower than average

What This Means

With a 27.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
110
Allowed After Appeal Filing
25
(22.7%)
Not Allowed After Appeal Filing
85
(77.3%)
Filing Benefit Percentile
27.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 22.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner CONIGLIO, AUDREA JUNE BUCKLEY - Prosecution Strategy Guide

Executive Summary

Examiner CONIGLIO, AUDREA JUNE BUCKLEY works in Art Unit 1617 and has examined 860 patent applications in our dataset. With an allowance rate of 55.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.

Allowance Patterns

Examiner CONIGLIO, AUDREA JUNE BUCKLEY's allowance rate of 55.0% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CONIGLIO, AUDREA JUNE BUCKLEY receive 2.18 office actions before reaching final disposition. This places the examiner in the 74% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CONIGLIO, AUDREA JUNE BUCKLEY is 31 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +21.8% benefit to allowance rate for applications examined by CONIGLIO, AUDREA JUNE BUCKLEY. This interview benefit is in the 70% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 20.8% of applications are subsequently allowed. This success rate is in the 15% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 28.9% of cases where such amendments are filed. This entry rate is in the 33% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 106.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 77% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 65.1% of appeals filed. This is in the 40% percentile among all examiners. Of these withdrawals, 55.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 55.0% are granted (fully or in part). This grant rate is in the 69% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.6% of allowed cases (in the 74% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.3% of allowed cases (in the 59% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.